Vantictumab, formerly known as OMP18R5, represents a novel cloned body designed to specifically inhibit osteopontin protein 18R5. Such approach is actively evaluated by researchers in potential applications in several https://bookmarks-hit.com/story25379315/vantictumab-a-thorough-dive-into-omp18r5-cloned-antibody